PIONEER REAL Japan: Baseline characteristics of a multicenter, prospective, real-world study of oral semaglutide in adults with type 2 diabetes in clinical practice in Japan.

Publisher: Asian Association for the Study of Diabetes and Blackwell Pub. Asia Country of Publication: Japan NLM ID: 101520702 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2040-1124 (Electronic) Linking ISSN: 20401116 NLM ISO Abbreviation: J Diabetes Investig Subsets: MEDLINE

Original Publication: Tokyo : Asian Association for the Study of Diabetes and Blackwell Pub. Asia

Diabetes Mellitus, Type 2*/drug therapy ; Glucagon-Like Peptides*/administration & dosage ; Glucagon-Like Peptides*/therapeutic use ; Hypoglycemic Agents*/administration & dosage ; Hypoglycemic Agents*/therapeutic use; Humans ; Male ; Prospective Studies ; Female ; Japan/epidemiology ; Middle Aged ; Aged ; Administration, Oral ; Blood Glucose/analysis ; Glycated Hemoglobin/analysis ; Adult

Aims/introduction: PIONEER REAL Japan was a non-interventional, multicenter, prospective study investigating oral semaglutide in adults with type 2 diabetes in routine clinical practice. We report baseline characteristics of participants enrolled in this study.
Materials and Methods: Adults aged ≥20 years with type 2 diabetes but no previous treatment with injectable glucose-lowering medication were enrolled. Participants initiated oral semaglutide at their treating physician's discretion and were followed for 34-44 weeks. Participants were stratified into <75-year-old and ≥75-year-old subgroups.
Results: A total of 624 participants initiated the study. The mean (standard deviation) age was 64.1 years (14.1), the mean (standard deviation) body weight was 72.4 kg (16.1), and the mean (standard deviation) body mass index was 27.5 kg/m ² (5.0). Participants had a median (interquartile range) type 2 diabetes duration of 9.3 years (4.2, 15.2) and mean (standard deviation) glycated hemoglobin 7.7% (1.1). Most (75.6%) participants were taking glucose-lowering medications at baseline; the most common was metformin (51.9%). The main reasons for initiating oral semaglutide were glycemic control and weight loss. Most (86.0%) participants had an individualized target for glycemic control of glycated hemoglobin ≤7%. The <75-year-old subgroup was heavier (mean [standard deviation] body mass index 28.6 kg/m ² [5.2] vs 25.1 kg/m ² [3.4]) but had comparable glycated hemoglobin levels (mean [standard deviation] 7.7% [1.2] vs 7.8% [1.0]) to the ≥75-year-old subgroup.
Conclusions: PIONEER REAL Japan describes the characteristics of individuals with type 2 diabetes prescribed oral semaglutide. The baseline characteristics provide insights into Japanese individuals with type 2 diabetes prescribed oral semaglutide in clinical practice.
(© 2024 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.)

Lancet Diabetes Endocrinol. 2022 Mar;10(3):193-206. (PMID: 35131037)
J Cardiovasc Dev Dis. 2023 Apr 18;10(4):. (PMID: 37103055)
Diabetes Care. 2013 Jun;36(6):1789-96. (PMID: 23704681)
Clin Exp Nephrol. 2019 Jan;23(1):1-15. (PMID: 30506489)
Diabetes Care. 2019 Dec;42(12):2272-2281. (PMID: 31530666)
Diabetes Care. 2022 Nov 1;45(11):2753-2786. (PMID: 36148880)
Diabetol Int. 2022 Dec 23;14(1):1-14. (PMID: 36636161)
Diabetol Int. 2017 Jun 27;8(4):375-382. (PMID: 30603343)
Diabetes Care. 1995 Jun;18(6):747-53. (PMID: 7555498)
Lancet Diabetes Endocrinol. 2022 Sep;10(9):623-633. (PMID: 35914543)
Lancet Diabetes Endocrinol. 2019 Jul;7(7):528-539. (PMID: 31189520)
J Diabetes Sci Technol. 2019 Nov;13(6):995-1000. (PMID: 30943790)
Lancet Diabetes Endocrinol. 2019 Jul;7(7):515-527. (PMID: 31189517)
Diabetol Int. 2020 Jul 24;11(3):165-223. (PMID: 32802702)
Diabetes Ther. 2018 Jun;9(3):1185-1199. (PMID: 29696567)
F1000Res. 2018 Jan 25;7:111. (PMID: 30026923)
Diabetes. 2002 Jul;51(7):2170-8. (PMID: 12086947)
BMJ Open Diabetes Res Care. 2020 Nov;8(2):. (PMID: 33188008)
Diabetes Obes Metab. 2015 Oct;17(10):974-83. (PMID: 26179187)
Diabetes Res Clin Pract. 2021 Aug;178:108845. (PMID: 33933501)
J Diabetes Investig. 2022 Jan;13(1):65-73. (PMID: 34191401)
Lancet Diabetes Endocrinol. 2020 May;8(5):392-406. (PMID: 32333876)
J Diabetes Investig. 2023 Jan;14(1):151-164. (PMID: 36562245)
Am J Kidney Dis. 2010 Jul;56(1):32-8. (PMID: 20416999)
Diabetes Ther. 2024 Mar;15(3):623-637. (PMID: 38240875)
Ann Intern Med. 2009 May 5;150(9):604-12. (PMID: 19414839)
Lancet Diabetes Endocrinol. 2020 May;8(5):377-391. (PMID: 32333875)
JAMA. 2019 Apr 16;321(15):1466-1480. (PMID: 30903796)
Diabetes Res Clin Pract. 2022 Jan;183:109119. (PMID: 34879977)
Diabetes Res Clin Pract. 2023 Sep;203:110841. (PMID: 37481115)
Lancet. 2019 Jul 6;394(10192):39-50. (PMID: 31186120)
Cardiol Res. 2022 Oct;13(5):303-308. (PMID: 36405226)
Diabetes Care. 2019 Sep;42(9):1724-1732. (PMID: 31186300)
J Diabetes Investig. 2020 Jul;11(4):1020-1076. (PMID: 33021749)
Diabetes Res Clin Pract. 2023 Apr;198:110599. (PMID: 36849048)
Diabetes Obes Metab. 2020 Apr;22 Suppl 3:21-34. (PMID: 32250528)
Diabetes Care. 2019 Dec;42(12):2262-2271. (PMID: 31530667)
Curr Diab Rep. 2015 Jun;15(6):602. (PMID: 25944304)

Novo Nordisk

Keywords: Prospective studies; Semaglutide; Type 2 diabetes

53AXN4NNHX (semaglutide)
62340-29-8 (Glucagon-Like Peptides)
0 (Hypoglycemic Agents)
0 (Blood Glucose)
0 (Glycated Hemoglobin)
0 (hemoglobin A1c protein, human)

Date Created: 20240507 Date Completed: 20240801 Latest Revision: 20240803

20240803

PMC11292382

10.1111/jdi.14219

38711208